Volume 25, Issue 4 (Iranian South Medical Journal 2022)
Iran South Med J 2022, 25(4): 394-407 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Emami-Ardekani A R, Karamzade-Ziarati N, Salehi Y, Manafi-Farid R, Fard-Esfahani A, Geramifar P, et al . Nuclear Imaging in Patients with Differentiated Thyroid Cancer and Negative Radioactive Io-dine Scan. Iran South Med J 2022; 25 (4) :394-407
URL: http://ismj.bpums.ac.ir/article-1-1644-en.html
URL: http://ismj.bpums.ac.ir/article-1-1644-en.html
Nuclear Imaging in Patients with Differentiated Thyroid Cancer and Negative Radioactive Io-dine Scan
Ali Reza Emami-Ardekani1 
, Najmeh Karamzade-Ziarati * 2, Yalda Salehi1 , Rehaneh Manafi-Farid1 , Armaghan Fard-Esfahani1 , Parham Geramifar1 , Davood Beiki1 , Mehdi Akhlaghi1 , Babak Fallahi1
, Najmeh Karamzade-Ziarati * 2, Yalda Salehi1 , Rehaneh Manafi-Farid1 , Armaghan Fard-Esfahani1 , Parham Geramifar1 , Davood Beiki1 , Mehdi Akhlaghi1 , Babak Fallahi1
1- Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran , n.karamzade@gmail.com
2- Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran , n.karamzade@gmail.com
Abstract: (1264 Views)
Background: Thyroid cancer is the most common endocrine malignancy in the world; however, these patients usually experience a high survival rate if they receive appropriate and timely treatment. Meanwhile, patients classified as having differentiated thyroid cancer with high thyroglobulin and negative iodine scan [Differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS)] are always considered a diagnostic-therapeutic challenge.
Materials and Methods: We conducted a comprehensive literature search of published papers in the PubMed/MEDLINE database regarding nuclear imaging in differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy. We included all human studies in this field.
Results: In this review, we examined four major groups of imaging studies aimed at identifying GLUT, SSTR, PSMA and FAP receptors in patients with TENIS. The diagnostic rate of 2-[18F]FDG PET/CT in these patients has been reported as 63-81% based on various studies. Also, [68Ga]Ga-DOTATATE PET/CT, [68Ga]Ga-PSMA PET/CT and [68Ga]Ga-FAPI PET/CT scans have shown good results in these patients.
Conclusion: [68Ga]Ga-FAPI PET/CT imaging has the highest diagnostic rate among these patients. Given the theranostic capability of FAPI and the numerous complications and limited inclusion criteria for treatment with tyrosine kinase inhibitors, it has been the next step in the treatment of patients with TENIS. Therefore, more extensive studies in this field are warranted.
Materials and Methods: We conducted a comprehensive literature search of published papers in the PubMed/MEDLINE database regarding nuclear imaging in differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy. We included all human studies in this field.
Results: In this review, we examined four major groups of imaging studies aimed at identifying GLUT, SSTR, PSMA and FAP receptors in patients with TENIS. The diagnostic rate of 2-[18F]FDG PET/CT in these patients has been reported as 63-81% based on various studies. Also, [68Ga]Ga-DOTATATE PET/CT, [68Ga]Ga-PSMA PET/CT and [68Ga]Ga-FAPI PET/CT scans have shown good results in these patients.
Conclusion: [68Ga]Ga-FAPI PET/CT imaging has the highest diagnostic rate among these patients. Given the theranostic capability of FAPI and the numerous complications and limited inclusion criteria for treatment with tyrosine kinase inhibitors, it has been the next step in the treatment of patients with TENIS. Therefore, more extensive studies in this field are warranted.
Type of Study: Review |
Subject:
Radiology. Diagnostic Imaging
Received: 2022/10/16 | Accepted: 2022/12/6 | Published: 2022/12/17
Received: 2022/10/16 | Accepted: 2022/12/6 | Published: 2022/12/17
References
1. Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 2012; 35(6 Suppl): 3-9. [PubMed]
2. Ardeshir Larijani Mb, Mohagheghi Sma, Mousavi Jarahi Sar, et al. Thyroid Cancer In Iran: An Epidemiological Survey Based On Cancer Data's Registered In Tehran. J Med Council Iran 2005; 23(4): 362-367. [Article]
3. Salari N, Kazeminia M, Mohammadi M. The Prevalence of Thyroid Cancer in Iran: a Systematic Review and Meta-analysis. Indian J Surg Oncol 2021; 2021(6): 1-11. [DOI]
4. Caetano R, Bastos CR, de Oliveira IA, et al. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative 131I whole-body scan results: A meta-analysis. Head Neck 2016; 38(2): 316-27. [DOI]
5. Kist JW, de Keizer B, Stokkel MP, et al. Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study. BMC cancer 2014; 14: 405. [DOI]
6. Emami-Ardekani A, Ghorbani-Nik F, Karamzade-Ziarati N, et al. Impact of TSH stimulation on 2-[18F]FDG PET/CT results in patients with papillary thyroid carcinoma presented with elevated serum thyroglobulin level and negative diagnostic iodine-131 whole-body scan. Iran J Nucl Med 2022; 30(2): 88-95. [Article]
7. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26(1): 1-133. [DOI]
8. Laha D, Nilubol N, Boufraqech M. New Therapies for Advanced Thyroid Cancer. Front Endocrinol 2020; 11: 1-9. [DOI]
9. Chao M. Management of Differentiated Thyroid Cancer with Rising Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scan. Clin Oncol (R Coll Radiol) 2010; 22(6): 438-47. [DOI]
10. Ma C, Kuang A, Xie J, et al. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 2005; 46(9): 1473-80. [PubMed]
11. Biermann M. Gallium-68-PSMA-PET/CT outperforms radioiodine scintigraphy and FDG–PET/CT in a prospective series of 10 patients with metastasized differentiated thyroid cancer. Clin Thyroid 2018; 30(8): 388-90. [DOI]
12. Shinto AS, Kamaleshwaran KK, Mallia M, et al. Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. World J Nucl Med 2015; 14(2): 101-8. [DOI]
13. Vrachimis A, Stegger L, Wenning C, et al. [68Ga]DOTATATE PET/MRI and [18F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2016; 43(10): 1765-72. [DOI]
14. Agrawal A, Rangarajan V. Appropriateness criteria of FDG PET/CT in oncology. Indian J Radiol Imaging 2015; 25(02): 88-101. [DOI]
15. Marcus C, Whitworth PW, Surasi DS, et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 2014; 202(6): 1316-29. [DOI]
16. Are C, Hsu JF, Ghossein RA, et al. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007; 14(11): 3210-5. [DOI]
17. Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48(2): 221-6. [PubMed]
18. Leboulleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007; 3(2): 112-21. [DOI]
19. Crippa F, Alessi A, Gerali A, et al. FDG-PET in Thyroid Cancer. Tumori 2003; 89(5): 540-3. [DOI]
20. Kukulska A, Krajewska J, Kołosza Z, et al. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. Eur J Endocrinol 2016; 175(5): 379-85. [DOI]
21. Giovanella L, Trimboli P, Verburg FA, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013; 40(6): 874-80. [DOI]
22. Vural GU, Akkas BE, Ercakmak N, et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 2012; 37(10): 953-9. [DOI]
23. Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int 2015; 2015: 917968. [DOI]
24. Atkinson H, England JA, Rafferty A, et al. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 2013; 94(3): 226-9. [DOI]
25. Treglia G, Rindi G, Rufini V. Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. Hormones (Athens) 2012; 11(3): 230-2. [DOI]
26. Görges R, Kahaly G, Müller-Brand J, et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11(7): 647-59. [DOI]
27. Czepczyński R, Gryczyńska M, Ruchała M. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment. Nucl Med Rev Cent East Eur 2016; 19(2): 67-73. [DOI]
28. Sager S, Kabasakal L, Halac M, et al. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers. Clin Nucl Med 2013; 38(5): 321-5. [DOI]
29. Padhy A, Chung SL, Kok TY, et al. Evaluation of thyroid cancer patients with Ga-68 DOTA-TATE PET/CT: initial experience at a tertiary health care centre. J Nuclear Med 2013; 54(2): 1928. [Article]
30. Demirci E, Kabasakal L, Ocak M, et al. Evaluation of 68Ga-DOTA-TATE and 68 Ga-DOTA-NOC PET/CT in patients with differentiated thyroid cancer. J Nuclear Med 2012; 53(1): 2095. [Article]
31. Jois B, Asopa R, Basu S. Somatostatin Receptor Imaging in Non–131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE: Low Fraction of Patients Suitable for Peptide Receptor Radionuclide Therapy and Evidence of Chromogranin A Level–Positive Neuroendocrine Differentiation. Clin Nucl Med 2014; 39(6): 505-10. [DOI]
32. Bychkov A, Vutrapongwatana U, Tepmongkol S, et al. PSMA expression by microvasculature of thyroid tumors–Potential implications for PSMA theranostics. Sci Rep 2017; 7(1): 5202. [DOI]
33. Derlin T, Kreipe HH, Schumacher U, et al. PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68Ga-PSMA ligand PET/CT. Clin Nucl Med 2017; 42(3): e173-e4. [DOI]
34. Abbasi M. Hypothesis Generation: Does Lu177 Therapy May be Effective for Treatment of Benign Prostate Hyperthrophy? Iran South Med J 2021; 24(6): 637-8. (persian) [Article]
35. Bertagna F, Albano D, Giovanella L, et al. 68Ga-PSMA PET thyroid incidentalomas. Hormones (Athens) 2019; 18(2): 145-9. [DOI]
36. Sollini M, di Tommaso L, Kirienko M, et al. PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome. EJNMMI Res 2019; 9(1): 93. [DOI]
37. Moore M, Panjwani S, Mathew R, et al. Welldifferentiated thyroid cancer neovasculature expresses prostate-specific membrane antigen—a possible novel therapeutic target. Endocr Pathol 2017; 28(4): 339-44. [DOI]
38. Lütje S, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med 2017; 42(1): 20-5. [DOI]
39. Verma P, Malhotra G, Meshram V, et al. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med 2021; 46(8): e406-e9. [DOI]
40. de Vries LH, Lodewijk L, Braat AJAT, et al. 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617. EJNMMI Res 2020; 10: 18. [DOI]
41. Ciappuccini R, Saguet-Rysanek V, Giffard F, et al. PSMA Expression in Differentiated Thyroid Cancer: Association With Radioiodine, 18FDG Uptake, and Patient Outcome. J Clin Endocrinol Metab 2021; 106(12): 3536-45. [DOI]
42. Fu H, Huang J, Sun L, et al. FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177LuFAPI-46. Clin Nucl Med 2022; 47(10): 906-907. [DOI]
43. Fu H, Fu J, Huang J, et al. 68Ga-FAPI PET/CT in Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy. Clin Nucl Med 2021; 46(5): 427-30. [DOI]
44. Chen Y, Zheng S, Zhang J, et al. 68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med 2022; 36(7): 610-22. [DOI]
45. Fu H, Fu J, Huang J, et al. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 2021; 46(11): 940-2. [DOI]
46. Ballal S, Yadav MP, Moon ES, et al. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for RadioiodineRefractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid 2022; 32(1): 65-77. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
